FDA Publishes Complete Response Letters Revealing Manufacturing and Data Gaps as Primary Reasons for Drug Rejections
More than half of FDA rejections stem from manufacturing concerns, primarily failed facility inspections.
41% of rejections due to poor product quality, including impurities and failed stability testing.
27% of CRLs cite insufficient clinical data, ranging from additional analyses to new Phase 3 studies.
74% of 202 CRLs from 2020-2024 involved quality/manufacturing issues like CMC problems.
FDA's public CRL repository, started in 2025, now includes nearly 350 letters for greater transparency.
Analyses from Jefferies, Mizuho, and Pharma Manufacturing highlight these as key stumbling blocks for sponsors.